An anti-cholesterol drug, new hope against COVID 19

An anti-cholesterol drug, new hope against COVID 19

A licensed drug normally used to treat abnormal levels of fatty substances in the blood could reduce infection caused by the SARS-CoV-2 virus by up to 70%, reveals a laboratory study conducted by an international collaboration of researchers and published in the journal Frontiers in Pharmacology.

The research team, led by the University of Birmingham and Keele University in the UK and the San Raffaele Scientific Institute in Italy, has shown that fenofibrate and its active form (fenofibric acid) can significantly reduce SARS-CoV-2 infection in human cells in the laboratory.

More importantly, the reduction in infection was obtained using concentrations of the drug that are safe and achievable with standard clinical dosing of fenofibrate.

Fenofibrate, which is approved for use in most countries around the world, is an oral drug currently used to treat conditions such as elevated blood cholesterol and lipid levels.

The team is now calling for clinical trials to test the drug in hospitalized patients with COVID-19, which will join the two clinical trials also underway in such patients in research led by the Hospital of the University of Pennsylvania in the United States and the Hebrew University of Jerusalem in Israel.

SARS-CoV-2, the virus that causes COVID-19, infects the host through an interaction between the Spike protein on the surface of the virus and the ACE2 receptor protein on host cells. In this study, responding to the global COVID-19 pandemic, the team tested a panel of already licensed drugs-including fenofibrate-to identify candidates that disrupt ACE2 and Spike interactions.

Once fenofibrate was identified as a candidate, they tested the drug’s efficacy in reducing infection in cells in the laboratory using the original SARS-CoV-2 virus strains isolated in 2020. They found that fenofibrate reduced infection by up to 70%.

Other unpublished data also indicate that fenofibrate is equally effective against new variants of SARS-CoV-2, including the alpha and beta variants, and its efficacy in the delta variant is under investigation.

Corresponding author Farhat Khanim, Ph.D., of the University of Birmingham, explains, “The development of new, more infectious variants of SARS-CoV-2 has led to a rapid increase in infection rates and deaths in several countries around the world, especially in the United States and Europe. While vaccination programs can be expected to reduce infection rates and the long-term spread of the virus, there remains an urgent need to expand our arsenal of drugs to treat SARS-CoV-2 seropositive patients,” he warns.

Alan Richardson, MD, of Keele University, adds that, “although vaccination programs are progressing rapidly in some countries, vaccine uptake rates are variable and, in most lower-middle-income countries, it is unlikely that a significant proportion of the population will be vaccinated until 2022”.

“Furthermore,” he continues, “although vaccination has been shown to reduce infection rates and disease severity, we are still uncertain about the strength and duration of the response. Therapies are still urgently needed to treat patients with COVID-19 who develop symptoms or require hospitalization.”

Co-author Elisa Vicenzi, Ph.D., of the San Raffaele Scientific Institute in Milan, says the data “indicate that fenofibrate may have the potential to reduce the severity of COVID-19 symptoms and also the spread of the virus.”

“Given that fenofibrate is a very inexpensive oral drug available worldwide, along with its extensive history of clinical use and good safety profile, our data have global implications,” he stresses, “especially in lower-middle-income countries and in those for whom vaccines are not recommended or are not appropriate, such as children, people with hyperimmune disorders, and those using immunosuppressants.

First author Dr. Scott Davies, also of the University of Birmingham, concludes that “further clinical studies are now urgently needed to establish whether fenofibrate is a potential therapeutic agent to treat SARS-CoV-2 infection.”

The research was conducted in collaboration with researchers from the University of Copenhagen (Denmark) and the University of Liverpool (UK).